Skip to main
ZYME

Zymeworks Inc (ZYME) Stock Forecast & Price Target

Zymeworks Inc (ZYME) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zymeworks is currently facing regulatory challenges and risks, which could potentially lead to delays in obtaining approvals or a failure to obtain approvals, impacting the company's valuation and overall success. The development and commercialization of pharmaceutical products is a highly regulated process, and issues with regulatory agencies can significantly impact the company's timeline and success. This presents a potential risk for investors to consider when assessing their outlook on Zymeworks's stock.

Bears say

Zymeworks is a clinical-stage biopharmaceutical company with a negative outlook due to potential competition from other companies with HER2-targeted therapies, uncertainty around its pipeline's clinical trial outcomes, and risks related to potential equity raises. Although Zymeworks has promising partnerships and a diverse pipeline, its limited financial resources may hinder its ability to reach profitability without additional funding. As a result, the company has a high dependency on the success of its clinical trials and licensing agreements to generate revenue.

Zymeworks Inc (ZYME) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zymeworks Inc (ZYME) Forecast

Analysts have given Zymeworks Inc (ZYME) a Buy based on their latest research and market trends.

According to 10 analysts, Zymeworks Inc (ZYME) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zymeworks Inc (ZYME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.